699 filings
Page 4 of 35
8-K
4k2vhqe30
2 May 17
REPROS THERAPEUTICS CORPORATE PRESENTATION MAY 2017 Dedicated to Treating Male and Female Reproductive Disorders
12:00am
8-K
xq40ydw qvrl
17 Apr 17
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions
12:00am
8-K
eqovw 6qw
13 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
c55jzkm g3kit8y
10 Apr 17
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids
12:00am
8-K
okvp7vw
31 Mar 17
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
12:00am
8-K
5cd2qrva6 kryldhomm
2 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
ez9pez zhrlmvuhcy
30 Jan 17
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids
12:00am
8-K
v9a1kszznb8aitpehz
19 Dec 16
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
12:00am
8-K
jfuhdgd4s uu
12 Dec 16
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids
12:00am
8-K
vcrat
7 Dec 16
Regulation FD Disclosure
12:00am
8-K
7s07ysee6 miugvjscg
15 Nov 16
Regulation FD Disclosure
12:00am
8-K
7t69ygr jq
14 Nov 16
Regulation FD Disclosure
12:00am
8-K
qtnypgojk ebm8ta32
8 Nov 16
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
12:00am
8-K
emf r3xq261is8lh
5 Oct 16
Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
12:00am
8-K
kn7t9 ei8
26 Sep 16
FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism
12:00am
8-K
osgnrakk0sj4
12 Sep 16
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
12:00am
8-K
wst8 916f
12 Sep 16
Regulation FD Disclosure
12:00am